 thromboprophylaxi patient hip fractur prospect compar studi org prospect assessor-blind trial thromboprophylact effect safeti heparinoid org mixtur low molecular-weight glycosaminoglycuronid patient hip fractur prestudi biostatist calcul need patient patient random major postpon surgeri analys patient intention-to-treat basi patient correct prophylaxi diagnosi deep vein thrombosi bilater phlebographi postop day frequenc deep vein thrombosi intention-to-treat basi org group dextran group basi correct prophylaxi differ signific two-month mortal rate equal group fatal pulmonari emboli dextran group patient dextran group postop transfus differ variou hemorrhag paramet org thromboprophylact effect patient hip fractur signific side effect